Teva Investigational Site 12961
Lenexa, Kansas, United States
NCT Number: NCT02215941
The primary objective of this study is to characterize the pharmacokinetics of TV-45070 in plasma following single and multiple-dose topical application of 8% TV-45070 ointment.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 1
Lenexa, Kansas, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
TV-45070 8% ointment
Placebo
Time frame: Day 8
Time frame: Days 1, 8, 15, 22, 29
Time frame: Day 8
Time frame: Days 8, 10
Time frame: Day 8
Time frame: Days 1, 8, 15, 22, 29
Time frame: Days 1, 8, 15, 29
Time frame: 10 Weeks
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study to Characterize the Pharmacokinetics and Safety of 8% TV-45070 Ointment Following 7.5 Days of Twice Daily Topical Application in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560150
Insulin Aspart, Pharmacodynamics
Chula Vista, California, United States
View Trial DetailsNCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsNCT03911050
Human Health, Pharmacokinetics
Kannapolis, North Carolina, United States
View Trial DetailsNCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial Details